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that they are useful (a) in identifying the organism in
women with symptoms but a negative potassium
hydroxide test, particularly if empirical treatment
aimed at uncomplicated vulvovaginal candidiasis has
already failed, and (b) before embarking on long term
suppressive antifungal treatment.10
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Liver cancer in low and middle income countries
Prevention should target vaccination, contaminated needles, and aflatoxins
Hepatocellular carcinoma affects more than500 000 people globally annually, and five yearmortality exceeds 95%.More than half of these
people are in China, and the incidence in sub-Saharan
Africa is also high.1 The causes of most of these cancers
are now known, and their prevention is possible.
More than 50% of hepatocellular carcinomas are
due to persistent (as opposed to transient) hepatitis B
infection, and around 25% are due to persistent hepa-
titis C virus.2 However, persistent hepatitis B infection
occurs primarily as a result of infection in the first five
years of life, whereas most hepatitis C infection occurs
in adult life. Thus primary liver cancer in younger indi-
viduals (under 50 years of age) is attributable to hepati-
tis B in more than 75% of the patients.
Aflatoxins are fungal toxins that commonly
contaminate maize, groundnuts, and other crops. They
play an important part in modifying the risk of liver
cancer associated with hepatitis B. After being metabo-
lised in the liver the toxin can bind to guanine in DNA,
resulting in mutations—for example in codon 249 of
the TP53 tumour suppressor gene. This mutation is
common in primary liver cancers from areas of high
exposure to aflatoxin, which provides evidence of a
carcinogenic role for the toxin.3 The effect of combined
exposure to persistent hepatitis B infection and dietary
aflatoxin has been shown best in a cohort study in
China.4 In that study the risk of liver cancer associated
with hepatitis B alone was a sevenfold increase over
background, but the combination of hepatitis B and
aflatoxin increased this to a 60-fold risk.
Preventing infection with these two hepatitis
viruses is one key strategy to reduce the burden of liver
cancer. Hepatitis B vaccination in infancy has been
shown dramatically to reduce persistent infection, with
vaccine efficacy against persistent infection of 94% at 9
years of age.5 In Taiwan vaccination has been
associated with a decline in primary liver cancer in the
youngest age group, which is difficult to explain other
than through an effect of vaccination.6 The critical
issue is that the child is protected for the first five years
of life when the risk of persistent infection is high. Even
if protection subsequently wanes only a small number
of persistent infections will result.
Although hepatitis B vaccine was first licensed for
use in 1982, the global use of the vaccine has been
incredibly low. This was partly as a result of the initial
high cost but also because of the lack of political will to
use a vaccine that would not have effects for at least two
decades. The development of a global vaccine fund has
transformed this situation. Through the global alliance
for vaccines and immunisation this fund is used to
introduce new and underused vaccines, including
hepatitis B, into the poorest countries of the world. If
the strategy proves financially sustainable (responsibil-
ity for securing funding for vaccines shifts onto the
countries in the period 2005-10) then future
generations will be spared liver cancer.
No vaccine is yet available for hepatitis C. Since the
major mode of transmission of this agent is by
contaminated needles the key strategy to prevent per-
sistent infection is by public health programmes for
safe injection. The World Health Organization recently
launched the safe injection global network (SIGN) to
this end.7 Again, if it is successful much liver cancer in
the older age groups will be prevented.
Prevention of infection with hepatitis B and C is
now promising but by its nature has to be a long term
strategy. At the same time there are some 350 million
carriers of hepatitis B virus in the world who continue
at high risk of cancer. What can we do for them?
This is where aflatoxin is important. We can poten-
tially modify risk by reducing or eliminating exposure.8
At an individual level this can be done by modifying
diet—but this is not an option for many of the affected
poor rural communities. Chemopreventive agents (for
example, oltipraz and chlorophyllin), which reduce the
burden of harmful aflatoxin metabolites in the body,
have been studied.9 Although of potential in targeted
individuals, this is unlikely to be a viable public health
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option for China and Africa. In contrast several
agricultural strategies reduce the quantity of aflatoxin
in food. Genetic modification of crops to enhance fun-
gal resistance is a promising method and biocontrol by
flooding fields with non-toxigenic fungi is another. But
much of the contamination of food occurs after the
harvest and during storage. Methods to reduce humid-
ity can limit fungal growth. Drying the crop in the sun,
on a mat, discarding visibly mouldy kernels or nuts
before storage, and using natural fibre sacks for storage
and placing these on wooden pallets to keep the crop
dry can be very effective.8 10 Rural communities can use
these techniques at minimal expense. We urgently
need to evaluate their impact on human exposure to
aflatoxin and implement them for the benefit of exist-
ing hepatitis B carriers—who make up 15-20% of many
populations at high risk.
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Safety and efficacy of combination vaccines
Combinations reduce distress and are efficacious and safe
For 130 years or more after Jenner introduced avaccine for smallpox this was the only vaccine ingeneral use. Ten vaccines are now included in
the routine childhood vaccination programme in the
United Kingdom , with multiple doses of most. The use
of combination vaccines reduces distress to the recipi-
ents and is likely to increase uptake rates. Many combi-
nations are as efficacious as the separate vaccines, but
the increasing number of antigens could theoretically
pose problems in terms of reduced immunogenicity or
increased reactogenicity.
Good post-marketing surveillance will become
important in monitoring both the clinical efficacy of
combination vaccines and adverse effects. With respect
to clinical efficacy this may be a particular problem
with combination conjugate vaccines. Using combina-
tion vaccines in the routine childhood programme in
the United Kingdom amounts to giving 11 injections
(24 in the United States), whereas, if given separately,
27 (almost 70 in the United States) would be needed.
The alternative approaches are combining as many
antigens into as few injections as possible, giving multi-
ple simultaneous injections, or giving the required vac-
cines over several visits. Generally parents tend to have
fewer concerns than health professionals about multi-
ple injections.1 2 However, it would seem cruel to give
more injections than required. In addition, if many
injections are due at the same time, some may be
delayed or not given at all.3 Pentavalent vaccines such
as diphtheria, tetanus, wholecell pertussis vaccine
(DTwP), Haemophilus influenzae type B (Hib) vaccine,
and inactivated polio vaccine (IPV) are widely available.
Hexavalent vaccines such as diphtheria, tetanus, acellu-
lar pertussis vaccine (DTaP), hepatitis B virus (HBV)
vaccine, IPV, and Hib are being developed.
The safety, efficacy, and immunogenicity of a com-
bined vaccine may be affected by interactions, not only
between the antigens but also between these and other
components such as adjuvants, stabilisers, and pre-
servatives. Research on combination vaccines is more
difficult than on single antigen vaccines because they
are often replacing widely used single vaccines, making
trials with placebos unethical. The disease may no
longer be common, so the production of antibodies or
immunogenicity, rather than protection from disease
(clinical efficacy), has to be assessed. This may be satis-
factory when antibody concentrations correlate closely
with protection, but for some diseases (for example,
pertussis) this is not the case. Thus post-marketing sur-
veillance is essential.
Combining vaccines into one product does not
increase the overall rate of adverse events, and with
some combinations, such as DTaP, the rates are lower
than when the component vaccines are given sepa-
rately.4 Schmitt et al compared antibody responses in
children receiving DTaP-HBV-IPV-Hib as one injection
with children receiving the same antigens but with the
Hib given at a different site. No difference was found in
adverse events associated with the different regimens.5
In 1998 a paper in the Lancet was interpreted as
showing a link between measles, mumps, and rubella
vaccine and pervasive developmental disorder and
bowel disease,6 even though the authors said they had
not proved such a link. Subsequent research has failed
to find evidence for this link 7 The suggested
mechanism behind the hypothesis was that combining
antigens produced an unpredictable response. Some
parents are concerned that multiple antigens may
overload the infant’s immune system. A recent review
set in context the antigenic load from vaccines in com-
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